Navigation Links
Lifesciences IT Spending to Experience Mature Growth Rates Despite Economic Slowdown, Declares Frost & Sullivan
Date:10/20/2009

LONDON, Oct. 20 /PRNewswire/ -- The global recession will have limited effect on the lifesciences industry. However, internal factors and external issues such as weak product pipelines, generic competition and declining market shares are pressurising lifesciences companies to cut down their IT budgets.

(Logo: http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO)

New analysis from Frost & Sullivan (http://www.healthcareIT.frost.com), Competitive Profiling of Market Participants in Lifesciences-IT, finds that the market was worth $26.5 billion in 2008 and is estimated to reach $41.6 billion in 2015.

"SaaS technology will be adopted by pharmaceutical companies as it is cost effective and offers enhanced flexibility options," notes Frost & Sullivan Industry Analyst E. Sujith. "The lifesciences industry is focusing on outsourcing its operations to reduce costs, creating a new market for vendors of IT solutions."

Pharmaceutical companies are moving to outsource operations to countries including India, China and Singapore as a cost-cutting measure. Despite the pharmaceutical industry increasingly rationalising and rightsizing its outsourcing, this still presents a substantial market.

Pharmaceutical companies are reducing their IT budgets. They are also rationalising new purchases due to uncertainties in the industry.

"Pharmaceutical and biotechnology companies are confronting issues such as a flood of generics, intensified competition, shrinking drug pipelines and lowered cash flows," cautions Sujith. "This is discouraging them from investing in IT-related expenses."

Accordingly, service providers should revise their pricing models. These could shift from effort-based pricing methods to potentially more successful outcome-based partnership contracts.

"The performance-based pricing model has been widely accepted in the marketplace during the recession and vendors would benefit by following this model," advises Sujith. "The IT cost efficiency compared to productivity of the business in exploring the cost is now a corporate wide strategy for maximising business productivity from the costs."

Competitive Profiling of Market Participants in Lifesciences-IT is part of the Healthcare & Life Sciences IT Growth Partnership Services programme, which also includes research in the following markets: European Medical Equipment Services Market, European market for Medical Display Monitors, Archiving Requirements for Image Management and European PACS Market. All research included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants.

If you are interested in a virtual brochure, which provides a brief synopsis of the research and a table of contents, then send an e-mail to Katja Feick, Corporate Communications, at katja.feick@frost.com, with your full name, company name, title, telephone number, company e-mail address, company website, city, state and country. Upon receipt of the above information, a brochure will be sent to you by e-mail.

Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best in class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best practice models to drive the generation, evaluation, and implementation of powerful growth strategies. Frost & Sullivan leverages over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 35 offices on six continents. To join our Growth Partnership, please visit http://www.frost.com.

Competitive Profiling of Market Participants in Lifesciences-IT

M3E1

    Contact:
    Katja Feick
    Corporate Communications - Europe
    P: +49 (0) 69 7703343
    E: katja.feick@frost.com

http://www.frost.com

SOURCE Frost & Sullivan


'/>"/>
SOURCE Frost & Sullivan
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Edwards Lifesciences Announces First Implants in U.S. Study of Minimally-Invasive Pulmonic Valve
2. R&D Spending by U.S. Biopharmaceutical Companies Reaches Record Levels in 2008 Despite Economic Challenges
3. Unemployment, Health Care Spending Affect Mortality
4. Cancer Drugs Emerging as Top Driver of Specialty Drug Spending
5. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
6. PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials
7. Schering-Plough Initiates Phase III Studies with Vicriviroc in Treatment- Experienced HIV Patients
8. Video: The Arizona Heart Institute Announces the Largest Worldwide Experience with Endoluminal Grafting to Treat Thoracic Aortic Aneurysms and Related Pathologies
9. Preimplantation Genetic Diagnosis International Society Refutes American Society of Reproductive Medicine Opinion - States Preimplantation Genetic Screening is Beneficial When Performed in Experienced Centers
10. Halozyme Therapeutics Announces Peer-Reviewed Publications of the INFUSE-LR Clinical Trial Results and Clinical Practice Experience With Hylenex
11. REMICADE-Treated Patients Experienced Rapid and Substantial Improvement in Psoriasis in Critical Regions of Body
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... Dec. 6, 2016   AlloSource , one ... bone, skin and soft-tissue allografts for use in ... Process Manager, for being named to the Board ... Quality Award by the Commerce Department,s National Institute ... commitment to process excellence. The Baldrige Award is ...
(Date:12/6/2016)... , Dec. 6, 2016   ... clinical-stage medical dermatology and aesthetics company, today ... privately held specialty pharmaceutical company focused on ... skin conditions, including psoriasis, atopic dermatitis and ... agreement, Sienna will make an undisclosed upfront ...
(Date:12/6/2016)... 6, 2016  Blueprint Medicines Corporation (NASDAQ: ... kinase medicines for patients with genomically defined diseases, today ... of $125,000,000 million in shares of its common stock. ... a 30-day option to purchase up to an additional ... in connection with the public offering. All shares of ...
Breaking Medicine Technology:
(Date:12/7/2016)... ... December 07, 2016 , ... Sharon Kleyne, host of the nationally syndicated radio ... on Voice of America, declared on her radio program in November 2016 the need ... when these bullies attack leaders in corporate America, they are trying to take advantage ...
(Date:12/7/2016)... ... December 07, 2016 , ... 1105 Media’s Live ... the Folio: Marketing Awards competition. Live From won in the Use of Social ... and ultimately successful projects undertaken by the media industry’s most innovative marketing professionals. ...
(Date:12/7/2016)... ... December 07, 2016 , ... Maureen McLaughlin, LA.c., a ... Medicine Associates of Connecticut (RMACT). McLaughlin brings nearly 20 years of experience with ... help patients realize their family building goals. Acupuncture helps fertility patients ...
(Date:12/7/2016)... NORFOLK, Va. (Dec. 3, 2016) , ... (PRWEB) ... ... the nation’s only patient advocacy nonprofit for individuals impacted by cerebral cavernous angiomas, ... work in New Mexico with a patient engagement program. New Mexico has more ...
(Date:12/6/2016)... ... December 06, 2016 , ... People ... can be seen on a type of MRI, according to a study appearing ... of the central nervous system characterized by tremors or trembling and stiffness in ...
Breaking Medicine News(10 mins):